Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
FACS, IHC, WB
Citations:
5
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
human, mouse
species reactivity (predicted by homology)
rat, porcine, bovine
technique(s)
flow cytometry: suitable, immunohistochemistry: suitable (paraffin), western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
ambient
target post-translational modification
unmodified
Gene Information
human ... TGFBR1(7046)
General description
TGF-beta receptor type-1 (UniProt: P36897; also known as EC:2.7.11.30, TGFR-1, Activin A receptor type II-like protein kinase of 53kD, Activin receptor-like kinase 5, ALK-5, Serine/threonine-protein kinase receptor R4, SKR4, Transforming growth factor-beta receptor type I, TbetaR-I) is encoded by the TGFBR1 (also known as ALK5, SKR4) gene (Gene ID: 7046) in human. TGF-beta R1 is found in all tissues examined and is most abundant in placenta and least abundant in brain and heart. It is also expressed in a variety of cancer cell lines. TGF-beta signaling involves its binding to the TGF-beta receptor type II (TGF-beta RII), which allows it to recruit TGF-beta receptor type I (TGF-beta RI) and assemble it as a heterodimeric receptor complex. TGF-beta RII phosphorylates TGF-beta RI in the glycine-serine (GS) rich region and activates the serine/threonine kinase activity of TGF-beta RI, which in turn phosphorylates receptor-linked Smad (Small mothers against decapentaplegic) proteins. To prevent any spontaneous phosphorylation of Smads, the inhibitor molecule FKBP12 binds to the GS region of the TGF-beta RI and blocks the access of TGF-beta RII to this domain. This inhibitory effect is removed upon TGF-beta binding to the receptor.
~56 kDa observed, 55.96 kDa calculated. Uncharacterized bands may be observed in some lysate(s).
Immunogen
KLH-conjugated linear peptide corresponding to 15 amino acids from the C-terminal region of human TGF-beta receptor 1.
Application
Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected TGF-beta receptor type-1 in human spleen, human cerebellum, human kidney, human pancreas, human placenta (chorionic villi), and human placenta (decidual cells).
Flow Cytometry Analysis: 1 µg from a representative lot detected TGF-beta receptor type-1 in one million mouse splenocyte cells.
Flow Cytometry Analysis: 1 µg from a representative lot detected TGF-beta receptor type-1 in one million mouse splenocyte cells.
This rabbit polyclonal Anti-TGF-beta Receptor, type I, Cat. No. ABF17-I is tested in Flow Cytometry, Immunohistochemistry (Paraffin), and Western Blotting for the detection of TGF-beta receptor type-1.
Biochem/physiol Actions
This polyclonal antibody specifically detects TGF-beta receptor type 1 in multiple species. It targets an epitope of 15 amino acids in the C-terminal region.
Analysis Note
Evaluated by Western Blotting in rat liver tissue lysate.
Western Blotting Analysis: 1 µg/mL of this antibody detected TGF-beta receptor type-1 in 10 µg of rat liver tissue lysate.
Western Blotting Analysis: 1 µg/mL of this antibody detected TGF-beta receptor type-1 in 10 µg of rat liver tissue lysate.
Other Notes
Concentration: Please refer to lot specific datasheet.
Replaces: ABF17
Still not finding the right product?
Try our Product Selector Tool to narrow your options
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuto Nakamura et al.
American journal of physiology. Heart and circulatory physiology, 318(2), H238-H251 (2019-11-28)
A disintegrin and metalloproteinase (ADAM)12 is considered to promote cardiac dysfunction based on the finding that a small-molecule ADAM12 inhibitor, KB-R7785, ameliorated cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of heparin-binding-EGF signaling. However
Giulio Bontempi et al.
Cell death & disease, 13(11), 965-965 (2022-11-18)
Histone acetylation/deacetylation play an essential role in modifying chromatin structure and in regulating cell plasticity in eukaryotic cells. Therefore, histone deacetylase (HDAC) pharmacological inhibitors are promising tools in the therapy of fibrotic diseases and in cancer. Peritoneal fibrosis is a
EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation.
Lin Zhang et al.
Nature communications, 13(1), 2543-2543 (2022-05-11)
Bone metastases occur in 50-70% of patients with late-stage breast cancers and effective therapies are needed. The expression of enhancer of zeste homolog 2 (EZH2) is correlated with breast cancer metastasis, but its function in bone metastasis hasn't been well-explored.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| ABF17-I | 04054839178993 |